MiNK Reports Narrower Q2 Loss and First Randomized Phase 2 Data for agenT-797
INKT sits 31% above its 52-week low of $8.48 on light trading volume (0.2× avg).
Summary
MiNK Therapeutics posted a narrower Q2 loss and shared early randomized Phase 2 data for agenT-797 in acute lung injury, with all treated patients alive at Day 28. The company also launched a paid named-patient access program in Brazil.
Key Events · Earnings and Guidance · INKT
-
Q2 Net Loss Narrows
Net loss was $3.1 million, or $0.62 per share, compared with $4.2 million, or $1.06 per share, in Q2 2025.
-
Cash Position Declines
Cash and cash equivalents fell to $8.8 million as of June 30, 2026, from $9.5 million at March 31, 2026.
-
Randomized Phase 2 Data
Initial Day 28 observations from the C-1300-02 trial showed all agenT-797-treated patients alive, with improved oxygenation and no major safety issues.
-
Named-Patient Access Program
First paid international named-patient access program established in Brazil, providing program revenue for product supplied.
Analysis · INKT · Life Sciences
MiNK Therapeutics reported a narrower Q2 net loss of $3.1 million, down from $4.2 million a year earlier, while cash declined to $8.8 million. The company also disclosed initial Day 28 observations from its randomized Phase 2 trial of agenT-797 in acute lung injury, showing all treated patients alive with improved oxygenation and no major safety issues. The first paid named-patient access program in Brazil adds a new revenue stream, though it is not a commercial launch. These updates matter because they provide the first controlled clinical data for the lead asset and clarify the company's cash runway amid a going-concern warning.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INKT was trading at $11.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $56.6M. The 52-week trading range was $8.48 to $18.17. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.